In an effort to mimic metformin and rapamycin, researchers used powerful screening methods to analyze over 800 natural compounds to assess their anti-aging potential and safety profile.
The Top-Performer series highlights papers published by Aging that have generated a high Altmetric attention score. Altmetric scores, located at the top-left of trending Aging papers, provide an at-a-glance indication of the volume and type of online attention the research has received.
By 2030, one in five Americans will age over 65 years old in the United States. As a society, an even larger aging population is fast on our heels. With age comes wisdom, and unfortunately, so does a number of costly and devastating diseases, including cancer, cardiovascular disease, Alzheimer’s disease, and Type II diabetes.
Researchers are currently working to mitigate the upcoming burden for this expanding population by developing anti-aging and anti-cancer drugs, and other geroprotective interventions that could extend healthspan, lower disease rates, and maintain productivity. However, the slow and expensive process of gaining approval for new potential pharmaceutical and nutraceutical interventions is historically arduous and prone to failure—especially when it comes to anti-aging and longevity research.
“Even if successful, to be used preventatively, anti-aging drugs face extraordinarily high safety and efficacy standards for approval [9].”
“One strategy to hasten the process has been the repurposing of existing, FDA-approved drugs that show off-label anti-cancer and anti-aging potential [10,11], and at the top of that list are metformin and rapamycin, two drugs that mimic caloric restriction [12].”
Metformin and rapamycin have already been FDA approved for use in renal transplants, Type II diabetes, and metabolic syndrome. These two drugs are both mTOR inhibitors which, through numerous research studies, have shown pleiotropic effects exhibiting multiple anti-aging, anticancer, and anti-cardiovascular disease benefits. However, some adverse side effects pertaining to extended use have made it so these two interventions (used alone) are unable to move forward for wide-scale preventative use.
“Taken together, rapamycin and metformin are promising candidates for life and healthspan extension; however, concerns of adverse side effects have hampered their widescale adoption for this purpose.”
Although there are some adverse side effects, the chemical structures of metformin and rapamycin should not be ignored. These two drugs can be analyzed, and even mimicked, to develop new, safer interventions to prevent and treat age-related diseases. The researchers in this study initiated an effort to identify nutraceuticals as safe, natural alternatives to metformin and rapamycin drugs.
“Nutraceuticals have received considerable attention in recent years for potential roles in preventing or treating a number of age-related diseases [88].”
The Study
“Our work is done entirely in silico and entails the use of metformin and rapamycin transcriptional and signaling pathway activation signatures to screen for matches amongst natural compounds.”
Test compounds were selected based on the natural compounds listed in the UNPD and Library of Integrated Network‐based Cellular Signatures (LINCS) datasets. Gene‐ and pathway‐level signatures of metformin and rapamycin were mapped and screened for matches against the over 800 natural compounds chosen. The team used conventional statistical methods, pathway scoring-based methods, and training of deep neural networks for signature recognition. Researchers applied several bioinformatic approaches and deep learning methods, including the Oncofinder, Geroscope, and in silicoPathway Activation Network Decomposition Analysis (iPANDA). The iPANDA extracts robust, biologically relevant pathway activation signatures from the data.
“In an application of these methods, we focused on mimicry of metformin and rapamycin, seeking nutraceuticals that could preserve their anti-aging and disease-preventive potential while being better suited for wide-scale prophylactic use.”
Results and Conclusion
“The analysis revealed many novel candidate metformin and rapamycin mimetics, including allantoin and ginsenoside (metformin), epigallocatechin gallate and isoliquiritigenin (rapamycin), and withaferin A (both). Four relatively unexplored compounds also scored well with rapamycin.”
Their initial list of over 800 natural compounds was condensed to a shortlist of candidate nutraceuticals that showed similarity to metformin and rapamycin and had low adverse effects.
“This work revealed promising candidates for future experimental validation while demonstrating the applications of powerful screening methods for this and similar endeavors.”
Click here to read the full research paper, published by Aging.
—
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
Aging Editorial Board member Dr. Alex Zhavoronkov discusses his 2020 research paper published by Aging, entitled, “Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections.”
Researchers explain their studies that were published in Aging
Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published in Aging. A new Behind the Study is released each Monday. Visit the AgingYouTube channel for more insights from outstanding authors.
—
Hello, my name is Alex Zhavoronkovand I’m the Founder and CEO of a company called Insilico Medicine. We are focused on the latest applications of artificial intelligence to drug discovery, biomarker development, and aging research. And I’m also a Chief Scientist at the Biogerontology Research Foundation. It’s a UK-based charity, 12 years old now founded in 2008. It’s called the Biogerontology Research Foundation because it’s focused primarily on biological and biomedical gerontology with support research worldwide. And we also conduct policy outreach, policy documents, and promote aging research worldwide.
We got into the coronavirus theme in mid-January as a company and also as an extended group of collaborators. At Insilico, we decided to go directly after viral proteins. So we have the ability at Insilico to identify new targets, but also to generate normal compounds very quickly using generative cell networks and reinforcement learning. So it’s kind of imaginative and strategy oriented AI to create molecules that specifically bind to the proteins of interest.
So we originally published and put out the paper and the molecules for the 3C-like main protease of the SARS-CoV-2. And we’re working with multiple collaborators worldwide to provide the molecules for their proteins of interest, and also we are generating a bunch of others. However, for the purposes of this paper we are not using AI in any way. It’s human intelligence and it is quite obvious that SARS-CoV-2 is more harmful to the elderly, the people over 50. So it’s infecting more people over 50, it is a much more severe and much more lethal in that age group.
So that is why it’s actually pretty unique compared to other viruses. So if you look at influenza and the other common viruses we do not see another virus, we do not see such effects in the elderly, so it’s a little bit more equal opportunity infections. For SARS-CoV-2 it infects mostly the elderly and there is actually no term to describe it right now. So in the paper that I put forward in Aging, I propose a new term so it’s gerophilic and gerolavic infection from Greek géros, old man and epivlavís, harmful. So it’s more harmful to the elderly, more severe in elderly. And gerophilic it’s géros again old man and philia is love, so it loves old people.
And if we’ll look at the data from Wuhan in China, you will see that 90% of the population, 89.7% of the population, who got the virus were over 30. And 99.2% of the population that died of it were over 30. So it’s really uneven distribution for both severe cases and lethal cases in the population. And one of the really important case studies that has been studied quite extensively is the Diamond Princess cruise ship. So the world’s most watched lab that came into attention because a few thousand people got stuck, very diverse population group was stuck on one cruise boat. And out of those few thousand, around 700 contracted the virus and most of them were over 65 and there were originally seven deaths, and a few more people died.
Figure 1.COVID-19 as a gerophilic and gerolavic infection.
And we see that people who had the infection, even with mild symptoms, they have dark spots in their lungs on CT. So it looks like they have some lesions and there is some fibrosis. Even if the disease has mild symptoms, in the elderly more so, it leaves the fibrotic trace. And in the paper, I’m hypothesizing that the disease is associated with immunosenescence. So both the involution of the thymus and many other processes that lead to immunosenescence. Immunosenescence leads to infection, so here you have of course chances of death. Infection leads to more damage and loss of homeostasis and that leads to accelerated aging. And also acceleration of age-related pathology also increase the chances of death that lead to more immunosenescence. So it’s kind of the vicious circle of immunosenescence and infection.
And there have been many studies in the past showing that some of the geroprotectors like sirolimus, rapamycin, are maybe effective in potentiating response to vaccines and also preventing infection in the elderly. So it’s paradoxical observation that immunosuppressant, like rapamycin, might have immunostimulatory effects. And there was anecdotal evidence showing that it protects the elderly from influenza and other virus not infections. It’s pretty obvious to try something like rapamycin that is reasonably safe in low doses. So in high doses it has substantial side effects, but in low doses it’s very well tolerated.
So there are others what is called rapalogs, very famous one is called everolimus. It’s so very close structural analog to sirolimus, developed by Novartis which has claimed to be selective to specific coattails and outdoor complex that make it more beneficial for aging and for other diseases. However, I would really like to see more evidence of that because those are very close structural analogs and there are other inhibitors that serve the same purpose. So 2013, Novartis conducted few experiments with everolimus, the drug is called RAD001 and demonstrated that in healthy elderly patients a low dose treatment with RAD001. Results in even potentiation and less infection with influenza and also potentiation of vaccines. So that was promising news.
So they published in 2014 in Science Translational Medicine and it was very promising study. Then in 2018, they showed that a combination of everolimus and another ToR inhibitor also results in immune potentiation and prevention of several infections, primarily influenza. So for influenza, they published in Science Translational Medicine, and a spinoff out of Novartis took those molecules into clinic, into Phase 3. And in Phase 3, they decided to instead of using everolimus, they used the molecule called BEZ235 rebranded as RTB101 which had high concentrations. It’s also a PI-3K inhibitor, so it’s not a very selective inhibitor or ToR, and they failed in Phase 3.
But they haven’t used RAD001 or sirolimus in combination or as control. I believe that it’s likely to be because of the molecule and also patient selection, so it should be biomarker used for that. But those promising early experiments clinical studies with RAD001 and also substantial evidence from the clinic met-studies showing that rapamycin is potentiating a vaccine response and immune status in the elderly. That gives us very promising data to try sirolimus in Phase 3 in low doses maybe once a week, maybe in combination with other geroprotectors like metformin, like NAD boosters, like senolytic to potentiate the immune system of the elderly before they get sick.
So in this paper, I also want to highlight that it’s not a medical advice, it’s not a recommendation, it’s a call for a clinical trials of an alternative view on how to address COVID-19 also SARS-CoV-2 and prevent infection and increase survival in the elderly, and also make it less severe for the elderly. So in this paper, I’m calling for clinical trials of rapamycin, a very well known geroprotector. It was actually implicated in Aging by Professor Mikhail Blagosklonny at Roswell Park in early 2000s. So 2004, 2005, 2006 with seminal papers showing that cancer agent is very likely to be also an anti-aging compound, and I now believe that this compound should be tried in multiple age associated pathologies and also for immmunosenescence, versing immunosenescence.
But other geroprotectors, promising geroprotectors, like metformin, can be very well combined with rapamycin, NAD boosters like nicotinamide riboside, nicotinamide mononucleotide may be tried in clinical trials. Senolytic, these could be tried also after COVID because of the fibrotic build-up, fibrosis in the lungs and also as rehabilitation after COVID. I think that some other promising geroprotectors including [inaudible] B3 activation. Again, that’s much less explored, could lead to gene clocks. So since 2013 there has been a revolution in gene clocks starting from our Panam and Horvath work showing that methylation data is very predictive of chronological age.
There are very highly accurate markers of aging but there are many others, so like lab tests, very simple clinical blood tests can be used to predict chronological age and my group published the first ones using deep learning. And there are many others including microbiomics aging clock, including imaging aging clocks, including transcriptomic aging clocks, and proteomics aging clocks, and whatever data there is longitudinal data that could be used to construct clocks should be collected during the clinical trials. And we should look at whether some of the molecules are making you younger or older compared to the chronological age from the various data types and look at the effects.
So that’s the current proposal on the paper, so I’m calling to try geroprotectors to protect the elderly, to potentiate their immune response to COVID, and also to try the aging clocks for both clinical trials enrollment and for monitoring to see what molecules are making you younger or older on pretty much every level. I’m also calling for those clinical trials because after COVID-19, after the epidemic is over, we’re going to have major economic consequences. There’s a lot of people who have been out of work, there’s been substantial capital influx from pretty much every government into the economy, so quantitative easing that might lead to inflation. We don’t know what’s going to happen to the economies of developed countries.
Previously, I published several papers and a book on economics of aging showing that increases in productive longevity would lead to substantial economic growth. If we manage to reduce the amount of money being spent on healthcare in the elderly by preventing disease and by rejuvenating the elderly, making them more resilient to disease, just that leads to unprecedented economic growth. And of course, if we make them more productive and contributing to the labor force longer, we will see unprecedented economic growth even further.
So we’re talking about double digit growth in developed countries. So here we can kill many birds with one stone, so to speak, even though I don’t like the word “kill.” And if we can try geroprotectors to prevent disease, but at the same time we can boost the economy after the epidemic is over if some of those geroprotectors show efficacy and people start believing more that aging is plastic and we can push the envelope in that area and really rejuvenate the elderly.
So that’s the paper and thank you very much for watching this. Stay healthy.
Click here to read the full study published in Aging.
—
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
Researchers conducted an eight-week study on diet and lifestyle among a small cohort of 43 male participants between the ages of 50 and 72.
The Trending with Impact series highlights Aging publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels. Look for future science news about the latest trending publications here, and at Aging-US.com.
—
Listen to an audio version of this article
In addition to the well-known personal and social costs of aging, the economic costs of aging are also considerably high. Research finds that investing in delaying aging is much more cost-effective than disease-specific spending. A study found that if Americans as a whole delayed their aging by 2.2 years (while extending healthspan), economic savings over 50 years could amount to a cumulative $7 trillion.
“The growing health-related economic and social challenges of our rapidly aging population are well recognized and affect individuals, their families, health systems and economies.”
The researchers organized a cohort of 43 healthy adult males between the ages of 50 and 72. Half of the participants (n=21) completed an eight-week treatment program, and the other half (control group=22) received no intervention. Interventions within the treatment program included regimented diet, sleep, exercise, relaxation guidance, and supplemental probiotics and phytonutrients. Prior to the treatment program, participants were enrolled in a preliminary education week to become acquainted with the researchers’ prescribed dietary and lifestyle interventions.
“To our knowledge, this is the first randomized controlled study to suggest that specific diet and lifestyle interventions may reverse Horvath DNAmAge (2013) epigenetic aging in healthy adult males.”
Diet Prescription
Researchers prescribed the participants with mostly (not entirely) plant-based diet instructions to consume measured portions of liver, eggs, dark leafy greens, cruciferous vegetables, colorful vegetables (excluding white potatoes and sweetcorn), beets, pumpkin seeds (or pumpkin seed butter), sunflower seeds (or sunflower seed butter), methylation adaptogens, berries, rosemary, turmeric, garlic, green tea, oolong tea, animal protein, and low glycemic fruit. They were prescribed two daily doses of PhytoGanix®, which is a combination of organic vegetables, fruits, seeds, herbs, plant enzymes, prebiotics, and probiotics. A daily two-capsule dose of UltraFlora® Intensive Care, containing Lactobacillus plantarum, was also prescribed.
General guidance included that participants should choose organic food products over conventional, and to consume “healthy” oils and balanced types of fat, including coconut, olive, flaxseed, and pumpkin seed oil. Participants were told to avoid consuming added sugar, candy, dairy, grains, legumes/beans, and to minimize using plastic food containers. In addition, the prescription instructed participants to stay hydrated and not to eat between 7pm and 7am.
Lifestyle Prescription
The participant exercise prescription was a minimum of 30 minutes per day for at least five days per week, at 60-80% intensity. They completed two 20 minute breathing exercises daily, using the Steps to Elicit the Relaxation Response process developed by Herbert Benson, MD. Participants were prescribed to sleep a minimum of seven hours per night.
Measuring Epigenetic Age
“Currently, the best biochemical markers of an individual’s age are all based on patterns of methylation [5].”
To extract DNA from the participants, researchers collected saliva samples and evaluated their RNA and DNA. They used methylation kits, assays, and the Horvath DNAmAge clock to conduct genome-wide DNA methylation analysis and calculate epigenetic age (DNAmAge) at the beginning of the study, and at the end.
“Horvath’s DNAmAge clock predicts all-cause mortality and multiple morbidities better than chronological age. Methylation clocks (including DNAmAge) are based on systematic methylation changes with age.”
Conclusion
According to the Horvath DNAmAge clock, participants in the treatment group scored an average 3.23 years younger at the end of the eight-week program when compared to participants in the control group. While these findings are meaningful, additional studies with a larger cohort size, longer duration, and other human populations will be needed in order to confirm these results.
“Notably, the shorter timeframe of this study and the scale of potential reduction, while modest in magnitude, may correlate with meaningful socioeconomic benefits, and appears to have the potential to be broadly achievable.”
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published in Aging. A new Behind the Study is released each Monday. Visit the AgingYouTube channel for more insights from outstanding authors.
Okay. So we met the first time at the Cold Spring Harbor Meeting on Mechanisms of Aging. And me and Julia went there with a lot of data and, if I remember correctly, we just realized that our aging study is so good that we can publish the wild-types only.
I think we realize that it had never been done in hybrid mice in both females and males. So just that we had hybrid mice, but also included both sex, made this study completely new, by just using wild-type mice.
Malin Hernebring
And we were so happy to meet you there, Jamie, and we had a nice discussion over our results and decided to take you on as a collaborator, which we’re very happy about.
Me as well, that was really fantastic, that was fun. I got to learn a lot about hybrid mice, which I had really had never thought about using before, to be perfectly honest. And especially learning about the body composition, which we’re going to talk more about. It was really a fun experience. So thank you. Both of you.
Julia Adelöf
Our pleasure.
Malin Hernebring
So you mentioned Julia, is that another aspect is that we include both sex. We talked about this a little bit before, how the research has changed, so that it has been so very focused on male mice. And now starting to realize the importance of including females in the study, especially since, I mean, women are many of the people that are taking the drugs that are developed.
Julia Adelöf
You see very real test, indeed. I think a lot of things has changed in the past, since we started the study, and nowadays there have been a lot of incentives to include both sex, which is a great thing. Our problem is though that, if you think about it, the tests that we use are predominantly, have been done with male mice for a long time. And that includes behavioral tests. So what was really important with our study, is that we follow these mice, both behaviorally, but also physiologically. And I’m going to come into the mobility test. To address depressive-like behavior, we used a common test called the forced swim test. And in this test, mice are placed in a water tank and then you record how they move in the water.
And both Malin and I had been taking… Were joining swimming teams at the time. And then you really get this feeling for that, people have different floating capacities or they act differently in water. And since we had the physiological data from these mice, we could see that the females had 50%, at the highest, more fat mass than the male mice. And as well, because we were swimming and thinking about this thing…
Malin Hernebring
…If I can just interrupt, because you were saying how, when you were crawling that you had to really have good speed and use your legs a lot to keep floating. While me having, maybe a bit more floating material, did not have that problem at all. So this is really positive of how we came this conclusion. And just thinking about crawling and how you line the water, whereas you’re floating.
Figure 1.Survival of C57BL/6N×BALB/c F2 hybrid male and female mice presented as intervals of natural lifespan.
Julia Adelöf
And I think one of the greatest things with our studies, that we actually included, the body composition when we were doing the data. And commonly it’s only the body weight, the differs, and we did not see a difference in the body weight. We saw that females and males weighed the same, but they had differences in lean mass and in fat mass. And then when we were looking at this a little bit more in detail, we actually saw that, how much the mice swam in water correlated, to how much percentage fat mass they had.
And this is also has never been shown before. I haven’t found a study where they actually address body composition and floating capacity. And since water tests are used for several different behavioral phenotypes, it’s very important in this study as well, that when you do water tests, that you actually take into account, differences in body weight. If you’re looking at obesity models, and as in our case, we found that there was a sex difference in water, but this sex difference could directly account for, by looking at the difference in the fat mass. So we cannot say, but there’s a strong correlation between immobility or activity in water and body composition.
Malin Hernebring
So we found that 46% in the younger mice, 46% of the difference was caused directly by the [inaudible] it’s…
And I mean, that’s a lot.
Jamie Ross
When you think about it that it really is a lot, because there’s a lot of behavior tests as Julia was mentioning. There’s more to water maze, which people classically use, which of course involves water and the ability to float. And how much muscle mass, how much fat mass you have, really directly can affect your ability to perform that task. Also, the radial arm maze can be filled with water as well. And these are all commonly used cognitive tests, that researchers use. And, again, I’ve never seen it published anywhere, where people are really thinking about how there are sex differences besides, sort of the place cells and how you use your environment. People usually focus on that aspect of the test, not the actual physical aspects.
Julia Adelöf
And I think that’s a challenge that we will see more of, now that both sexes are included in the studies. Because we are so focused on measuring one thing, which is depressive-like behavior in this case. And we don’t think about, “okay, so what are the other sex differences?” Because where you found a difference, and that’s super interesting, but can that actually be explained by something, like in this case, physiological. And that’s why data can be very misinterpreted, if we don’t know what kind of confounding effects, due to other sex effects that is involved in, or is interfering with our results. So I think it will be interesting to see, and I think that our study was early, because we included Themis mice early. But I think this kind of sex-different perspective and the secondary effects, will be even more common in the literature from now on.
Malin Hernebring
I would think so too, and hopefully also… I mean, one of the reasons that we’re doing this now, is to spread this information, so that people will know that there is this correlation. But I’d like to go through a bit, about this reduced exploratory behavior as a conserved hallmark. So one aspect of this study is that, because we are euthanizing animals that are suffering from severe disease, we are looking specifically at aging and not features that come along with decease. So I think this makes our results stronger also, and the fact that what we do see is a reduction in exploratory behavior, while we don’t see any effect on memory, for example, which we were surprised to see.
Interestingly, we neither see an effect in bone density with aging. I mean the old cohort that we’re using, they are not… So they’re at a stage where it’s about 70% survival. So they started to die, but they’re still, relatively healthy. And this was by choice that we chose this, because we didn’t want to have a selection on the cohort, that we looked at. We didn’t want to study the ones that were extremely long-lived only, we wanted to know more about the whole population.
Julia Adelöf
I think it can explain it also, because it’s a difference between aging mice and dying mice.
Jamie Ross
The lifespan and the new way to try to approach it, I think, that’s a really good point. You put an animal in an open field, and an aged animal, and if they have these other comorbidities, you’re not sure if they are moving less, because they actually are moving less. They have sarcopenia and these other issues, or maybe they have some arthritis, or they’re moving less because, wow, they’re actually in pain, because they have a disease.
Julia Adelöf
And that’s a challenge in the aging field, because you want to do research on old mice. But how do you do the discrepancy between dying mice and old mice? And I think one of the reasons why we actually, that we used in our protocol as well. Is that we removed animals with diseases, also helped us forming a cohorts of aging mice and not dying mice.
Figure 2.Physiological parameters of mice in the cohorts for behavioral assessment.
Malin Hernebring
So basically this method is about giving an estimate of the so-called life span. I mean, traditionally life span experiments are conducted until the animals are… Or they are allowed to live, for as long… That they are considered so sick from disease so that they are not likely to survive for another week and that means that they could go for months or even years with big tumors. Ethically, that’s very problematic, but as we were talking about, it’s also can complicate other analysis of course. But the way that we do this then is that, when we euthanize these animals, we make two curves.
One curve, we count these animals as if they had died from natural causes, and that’s, of course, is an underestimation. And then we make another curve that we calculate these animals as if they were as healthy as their litter mates, which they were not, because they had a terminal illness. So then that’s an overestimation of the life span, so then we have an interval that will be the min and max of this life span. We think this is a really good method, that we hope people will start using, in life span analysis.
Jamie Ross
I think it’s really fantastic, actually. The more and more I think about it, I know that maybe I’m biased. But so many institutions are not allowing researchers, for obvious reasons, to perform life span studies any more because they do not want the animals, understandably so, to be in pain and to be sick. So this is actually a really nice way to say, “Hey, I’m doing a life span analysis, however, I’m going to euthanize the animals who are sick and still get good, solid data that I can use.”
Julia Adelöf
And compared to other aging studies, because that was one of our issues that, we wanted to euthanize our animals upon early signs of disease. But since no other aging studies, that we found had euthanized the same amount or the large percentage of mice, we knew that it will be different because of course they will have a longer life span. But since we created the this, we could actually compare our data with it, even though we use the different protocol, with a lot of other aging studies in the fields, which is also important to know the platform, and to also compare your research against what’s known in the literature.
Malin Hernebring
And to be able to define the age status of your cohorts you’re looking at. I mean, yeah. And this was initially in the paper that we submitted, I don’t remember where now, but it was part of the review… it’s comments, that the animals are probably not feeling so well, because they have such a short life span. And that’s when we started to think about this and to invent this method, basically.
Jamie Ross
Are we going to go back and talk about the exploratory behavior a little bit more? Because one point that I wanted to also mention was, I think that this is a really nice, easy way to monitor what’s going on with the animals because there’s no cognitive testing involved, in the sense that, you don’t have to worry, “Oh, I’m using males or females so I shouldn’t use this for the females, I shouldn’t use this test for the males.” It’s a conserved test, that you can use for both males and females. It’s easy in the sense that it requires, not an absurd amount of equipment. And you put the animals there and then you walk away, and you let them stay in that environment for an hour, hour and a half, and then you look at the first 10, 15 minutes of that exploratory time. And I think that is also something really nice that people … I hope other researchers see and think how they could incorporate that measurement into their aging analysis of the animals.
Julia Adelöf
Yes and that it’s easy to do opens up for a lot of people to do it. But I think also one of the findings of this paper was that we found exploratory behavior to decrease, that we didn’t find learning and memory. And when you look at a lot of behavioral testing, they have an exploratory or exploration component in their tests. And since we found, they could show that, in a hybrid background, in both females and males, this declines. My question, is exploratory behavior and the decline an exploratory behavior, are confounding effects of other results, that has been shown of learning and memory? Because they are based on exploratory components as well. So I think, also when you perform aging studies, you should actually assess the exploratory behavior, to be able to know what your other behavioral tests show, since we have these components integrated into the test.
Jamie Ross
That’s a very good point. We always try to do a light-dark test and some sort of transition test to make sure that they are perceiving their environment correctly and that they move correctly, as well as the open field and other things. So, yeah, I think that’s a really good point to make, that I hope other researchers, who want to study aging more and other age-related diseases, think about.
Julia Adelöf
And also to be cautious about when you do a behavioral test and you have a test battery, is preferable, if you do the open-field tests early on, because you can also see a change. If you do open field test, we learned our lesson. If you do it later, you can actually change the order. So you want to have it early on, in the behavioral test battery. And then you would know also, if you find differences and you need to exclude results from following analyses and tests.
Malin Hernebring
And also that the animals are affected by being handled, so their exploratory behavior will change. We know now it’s hard to compare them.
I had another comment on this…this DXA equipment may not be standard in all laboratories.
Julia Adelöf
For body composition, the DXA. I don’t think everyone knows, the DXA is used for measuring the body composition of mice and rodents in this different type.
Malin Hernebring
Exactly. I don’t know, maybe someone has done this, but I’m just thinking that one way, instead to do this, would be to analyze the density of the mouse. I mean, basically just putting them in water and see how much volume that goes out. And then that would be some kind of measure of what the mouse density is. I’m hoping they’re not taking up.
Julia Adelöf
Mice float, they’re known to float and they don’t do this themselves, but if they’re not naked mice, they do float. And I was thinking, yeah, I think it would be an excellent follow-up to actually look at. And I think it has been done at positioning, so I know that it’s a paper out where they have tried to remove the [inaudible], so they added detergent into the water and then they could see that the position of the mice changed. So it has been shown that the…
Malin Hernebring
…The buoyancy.
Julia Adelöf
…Yeah, but that has not been done in in behavioral tests. So you can see that they do change their position and their angle in the water, but they haven’t correlated this to anything.
Malin Hernebring
Okay. So the take home messages from this work are that we want you all to know that the main conserved hallmark of aging behaviorally, is a decreased exploratory behavior. And we want you to be aware when you’re doing water-based tests to… as a body composition because fat mass can correlate to behavior in water-based tests. And also we want everyone using or doing a lifespan analysis, to think about the ethics surrounding the lifespan analysis and also be aware that there is a method to calculate lifespan, in which animals that suffer from severe disease or from pain, can be euthanized and still give valuable data. I’d like to thank the Swedish Foundation for Strategic Research, SSF for funding Julia’s PhD and also Jamie Ross and contributors to you. I think that’s all we had, right?
Julia Adelöf
Thank you for listening.
Malin Hernebring
Thank you for listening.
Jamie Ross
Thank you.
Click here to read the full study published in Aging.
—
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
Dr. Mikhail Blagosklonny gleans an important new discovery in aging research—deduced from recent studies on short-lived mice and rapamycin.
The Top-Performer series highlights papers published by Aging that have generated a high Altmetric attention score. Altmetric scores, located at the top-left of trending Aging papers, provide an at-a-glance indication of the volume and type of online attention the research has received.
The exact mechanisms at play in the human aging process are still up for debate. A number of great minds in science have proposed plausible aging mechanisms and theories, such as DNA damage, telomere shortening, and DNA damage theories of aging. DNA damage theories suggest that aging is functional decline, caused by the accumulation of molecular damage. However, some scientists counterclaim that neither DNA damage nor telomere shortening limit lifespan or cause aging.
Rapamycin is a macrolide antibiotic that has immunosuppressive properties, regulates a key cellular growth pathway (mTOR), and has been at the center of numerous studies of aging since its discovery in 1964. Dr. Blagosklonny explains that, based on findings from recent mouse-model studies of rapamycin’s effects on short-lived mice, normal aging is not caused by the accumulation of molecular damage or telomere shortening.
“Here I discussed new evidence that normal aging is not caused by accumulation of molecular damage or telomere shortening: while extending normal lifespan in mice, rapamycin failed to do so in mice dying from molecular damage (Figure 1).”
Evidence From Rapamycin
In the study which Dr. Blagosklonny refers to, researchers genetically modified mice to artificially shorten telomeres, administered rapamycin to normal mice and the telomerase-deficient short-lived mice, and observed the effects. In normal mice, results were congruent with a number of other studies that found lifespan was significantly extended. In the telomerase-deficient mice, lifespan was shortened as a result of rapamycin.
“While shortening lifespan by 18% in unnatural telomerase-deficient mice, in the same study in natural mice, rapamycin increased lifespan by 39% and healthspan by 58% (measured as tumor-free survival) [3].”
Given that rapamycin prolongs life in normal mice, Dr. Blagosklonny asserts that this study proves that normal lifespan is not constrained by telomere length. Telomeres only become life-limiting when they are artificially shortened to the point where rapamycin can no longer extend lifespan. Furthermore, Dr. Blagosklonny explains that although molecular damage and telomere shortening could be life-limiting, they ultimately do not limit life because quasi-programmed aging occurs at a faster rate.
“Although molecular damage accumulates, this accumulation is not life-limiting because quasi-programmed aging terminates life first (Figure 1A). Quasi-programmed (hyperfunctional) aging is life-limiting, because it is favored by natural selection.”
“According to hyperfunction theory, aging is quasi-programmed, a continuation of developmental growth programs, driven in part by hyper-functional signaling pathways including the mTOR pathway [9].”
He explains that hyperfunction is an excessive, yet normal function that occurs later in life. Hyperfunction in this context does not necessarily mean an increase in function and, in some cases, it even means a decrease in function. The same pathways and functions that drive growth and development earlier in life, also drive age-related diseases later in life. Dr. Blagosklonny proposes that quasi-programmed (hyperfunctional) aging is favored by natural selection and is what limits life.
“It is hyperfunctional signaling pathways such as mTOR (one of many) that drive both growth and aging, causing age-related diseases that in turn damage organs, leading to secondary loss of function.”
Many signaling pathways interact with mTOR to drive aging, forming a network, including MEK/MAPK, NF-kB, p63, HIF-1, and many others. Dr. Blagosklonny suggests that, in theory, there could be a number of mTOR-independent factors of quasi-programmed aging that are life-limiting, as well. He goes on to exemplify several lines of evidence concluding that it is not molecular damage that causes normal aging or limits life—it is normal, quasi-programmed (hyperfunctional) aging.
Conclusion
Dr. Blagosklonny mentions a forthcoming review that will be entitled: “When longevity drugs do not increase longevity: Unifying development-driven and damage-induced theories of aging.”
“Once again, damage accumulates and must cause death eventually, but quasi-programmed (hyperfunctional) aging terminates life first. Molecular damage can become life-limiting, when artificially accelerated or, potentially, when quasi-programmed aging is decelerated.”
Click here to read the full research perspective, published in Aging.
—
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
Researchers used nationally representative data to examine the relationship between sleep disturbance and deficiency and their risk for incident dementia and all-cause mortality among older adults.
Listen to an audio version of this article
Are serious health consequences looming for those with trouble sleeping? Based on a large sum of available research, the answer appears to be yes—poor sleep poses an increased risk of dementia and all-cause mortality. But what defines poor sleep? Conflicting results have been reported by researchers regarding the characteristics of sleep when examining incident dementia and all-cause mortality. For instance, one meta-analysis suggests that sleeping fewer than five hours (short sleep) andlonger than nine hours (long sleep) per night is associated with greater risk of mortality. Another meta-analysis finds that only longer than nine hours is associated with greater risk of mortality.
“Research on sleep disturbance and deficiency and all-cause mortality therefore has shown conflicting results. Further, few studies have included a comprehensive set of sleep characteristics in a single examination of incident dementia and all-cause mortality.”
The researchers collected baseline data from the National Health and Aging Trends Study (NHATS). The NHATS is a nationally-representative longitudinal study of Medicare beneficiaries (65 years and older) in the United States. The data were collected from a randomly selected subset of 2,812 participants from the NHATS population that were administered sleep questionnaires in 2013 and 2014.
“Participants with dementia at baseline (year 2013) were excluded (n = 202) for a sample of 2,812 with sleep data in either 2013 or 2014.”
The sleep characteristics measured from the questionnaire were: sleep duration, sleep latency, difficulty maintaining alertness, sleep quality, napping frequency, and snoring. First, participants rated their memory and performed a memory-related activity to assess their cognitive capacity and screen for incident dementia. Body weight was reported by participants annually, and diagnosis of heart attack, heart disease, hypertension, arthritis, diabetes, stroke, and cancer were also self-reported. Annual interviews were conducted to record instances of participant mortality. The researchers used Cox proportional hazards modeling and controlled for confounders to examine each sleep characteristic and outcome.
Results
“Overall, our findings show a strong relationship between several sleep disturbance and deficiency variables and incident dementia over time.”
In the results adjusted for confounders, the team found that longer time to fall asleep and shorter sleep duration predicted incident dementia. They also found that short sleep duration, difficulty maintainingalertness, napping, and poor sleep quality predicted all-cause mortality. Given that short sleep duration was a strong predictor for both incident dementia and all-cause mortality, the researchers suggest that this may be the most important sleep characteristic related to adverse outcomes among older adults.
“The association observed in our study between short sleep (5 hours or less) and incident dementia screening may be understood via the research drawing upon animal models to demonstrate brain toxin removal during sleep [24].”
Another fascinating finding from this study was the difference between unadjusted and adjusted results for long sleep. As mentioned, previous studies have shown that long sleep is associated with both incident dementia and all-cause mortality. However, after the researchers adjusted for confounders, such as age and chronic conditions, the association between long sleep and incident dementia and all-cause mortality disappeared. The relationship between short sleep and both incident dementia and all-cause mortality remained significant even after full adjustment. These findings stand in contrast to the meta-analyses initially mentioned that have found associations between both short and long sleep and all-cause mortality in adults. The researchers suggest the cause may be that long sleep is a reflection of underlying disease.
“The most parsimonious explanation for the disappearance of the effect of long sleep on dementia and mortality in adjusted models is that the deleterious impact of long sleep is a reflection of underlying disease.”
Conclusion
The researchers confirm that addressing the sleep disturbance and deficiency variables in this study may have a positive impact on risk for incident dementia and all-cause mortality among older adults.
“Also, future research may consider the development of novel behavioral interventions to improve sleep among older adults.”
Aging is an online open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues, and other researchers, far and wide.
As the world continues to account for COVID-19, this year the American Association for Cancer Research (AACR) Annual Meeting will be a virtual event. Aging, by Impact Journals, is proud to be a participant in the conference on April 10-15 and May 17-21, 2021.
Listen to an audio version of this article
BUFFALO, NY-MARCH 25, 2021 – Aging is indexed by PubMed/Medline abbreviated as “Aging (Albany NY)”, PubMed Central, ISI/Web of Science: Science Citation Index Expanded (abbreviated as Aging‑US and listed in the Cell Biology category; since June 2017 it has also been listed in the Geriatrics & Gerontology category), and Scopus /Rank Q1 (abbreviated as Aging).
Every year, the American Association for Cancer Research (AACR) organizes a conference program that covers the latest discoveries in cancer research. Topics include population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy. This conference aims to highlight work from the best minds in research and medicine from institutions all over the world. The journal Aging,byImpact Journals, will be participating at the AACR Annual Meeting this year.
Impact Journals is an open-access publisher of rigorously peer-reviewed scientific literature, and owns four medical research journals, including Aging. Aging was launched by Impact Journals in 2009 with the goal of spotlighting high-impact papers, authored by scientists who study the process of aging and age-related diseases—including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome.
Aging has published outstanding papers and reviews by highly-cited authors and award winners, including Andrew V. Schally (Nobel Laureate), Shinya Yamanaka (Nobel Laureate), Lawrence Donehower, Toren Finkel, Stephen Helfand, Gerald Shadel, Andre Nussenzweig, Maurice Burg, Karen Vousden, Leonard Guarente, and Dale Bredesen. Importantly, the Aging Editorial Board also comprises numerous prestigious award winners, including Nobel Laureate Elizabeth H. Blackburn, and many other distinguished scientists, including Cynthia Kenyon, Judith Campisi, Leonard Guarente, Michael Hall, Mikhail Blagosklonny, Vera Gorbunova, David Sinclair, Jan Vijg, and Thomas Rando.
The journalhasrecently concluded its 12th year of publishing and has become Impact Journals’ featured journal. Learn more about Aging and Impact Journals at the virtual 2021 AACR conference on April 10-15 and May 17-21, 2021. Registration will be open through the beginning of the event.
About Aging:
To learn more about Aging, its publication standards, and past or current issues, visit www.aging-us.com.
Impact Journals is an open-access publisher with four scientific journals: Aging, Oncotarget, Genes & Cancer, and Oncoscience. Our mission to provide scientists with the opportunity to share their exceptional discoveries, offer services that enable rapid dissemination of results, and to present vital findings from the many fields of biomedical science. Our goal is life without disease.
Impact Journals LLC, 6666 E.Quaker St. Ste. 1, Orchard Park, NY 14127
For the first time, researchers demonstrate that hyperbaric oxygen therapy can reverse the mechanisms that mark the aging process.
Oxygen molecules and erythrocytes floating in a vessel in the blood stream.
Listen to an audio version of this article
Aging is the progressive loss of physiological integrity, which results in impaired functionality and increased susceptibility to diseases, and ultimately death. For the first time, researchers collaborated in an in vivo study to observe the effects of hyperbaric oxygen therapy on cellular mechanisms to reverse aging.
“At the cellular level, two key hallmarks of the aging process include telomere length (TL) shortening and cellular senescence.”
Telomere Length
Telomeres (TLs) function to protect chromosomes from DNA damage and are located at the end of the chromosome. In each instance of cell division, the telomeres shorten due to an inherent inability to fully replicate the DNA strand. Given that cells can only replicate a finite number of times before they can no longer engage in mitosis, the shortening of telomeres has been shown in adults to lead to increased rates of mortality.
Researchers in this study also provide examples of studies that are finding a number of pharmacological agents capable of reducing the shortening rate of telomeres.
“Shortened TLs can be a direct inherited trait, but several environmental factors have also been associated with shortening TL, including stress, lack of physical endurance activity, excess body mass index, smoking, chronic inflammation, vitamins deficiency, and oxidative stress [2, 8, 9].”
Cellular Senescence
The other hallmark mechanism of the aging process is cellular senescence. Previously, senescent cells have been viewed as mechanisms that protect the body against cancer through cell-cycle arrest, however, recent discoveries have found that they also have a role in processes such as development, tissue repair, aging, and age-related disorders. The phase of senescence can be triggered by telomere shortening and other non-telomeric DNA damage.
“The primary purpose of senescence is to prevent propagation of damaged cells by triggering their elimination via the immune system. The accumulation of senescent cells with aging reflects either an increase in the generation of these cells and/or a decrease in their clearance, which in turn aggravates the damage and contributes to aging [1].”
Oxidative Stress
In this well-written paper, the researchers introduce the topic by citing numerous interventional studies measuring the association between telomere length and lifestyle modifications. Studies include the measuring of diet, supplements, physical activity, stress management, and social support. However, the team found that the most common mechanism associated with telomere shortening is oxidative stress.
“Oxidative stress can occur from imbalances between the production of reactive oxygen species (ROS) and cellular scavengers.”
Previous studies indicate that telomeres are highly sensitive to oxidative DNA damage which occurs due to an excess of reactive oxygen species (ROS), or molecular oxygen by-products. The excess formation of these ROS occurs through the sequential reduction of oxygen via the addition of electrons and a lack of scavenger cells to digest excess microorganisms. This leads to the shortening of telomeres.
Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy (HBOT) has been observed to stimulate brain function and increase cognitive ability in previous studies. HBOT involves patients breathing in 100% oxygen in a pressurized chamber on a repeated basis. Being in this type of environment increases the amount of oxygen that is dissolved in the blood and tissue. Increasing oxygen levels in the body using pure oxygen on a daily basis can induce the hormesis phenomenon. This eustress type of therapy has been shown to have beneficial and positive effects on the body and mind.
“Single exposures [to HBOT] increase ROS generation acutely, triggering the antioxidant response, and with repeated exposures, the response becomes protective [13, 18].”
The Study
This study was designed to evaluate the effects of HBOT on the telomeres and concentrations of senescent cells in aging/healthy adults. Thirty-five participants living independently at 64+ years of age received HBOT exposures daily, over the course of 60 days.
Researchers collected whole blood samples prior to intervention (baseline), at the 30th and 60th session, and 1-2 weeks after the last HBOT session. They assessed the telomere lengths and senescence of peripheral blood mononuclear cells (PBMCs) in each participant’s blood sample.
Figure 3. Senescent cell changes with HBOT.
“In this study, for the first time in humans, it was found that repeated daily HBOT sessions can increase PBMC telomere length by more than 20% in an aging population, with B cells having the most striking change. In addition, HBOT decreased the number of senescent cells by 10-37%, with T helper senescent cells being the most affected.”
Conclusion
Following HBOT, telomere lengths increased by over 20% in T helper, T cytotoxic, natural killer, and B cells. There was also a significant decrease in the number of senescent T cytotoxic and T helper cells observed in the participant blood samples, allowing for new healthy cells to regenerate.
“In conclusion, the study indicates that HBOT may induce significant senolytic effects including significantly increasing telomere length and clearance of senescent cells in the aging populations.”
Click here to read the full scientific paper, published in Aging.
Learn more about Hyperbaric Oxygen Therapy (HBOT)
—
Aging is an open-access journal that publishes research papers monthly in all fields of aging research and other topics. These papers are available to read at no cost to readers on Aging-us.com. Open-access journals offer information that has the potential to benefit our societies from the inside out and may be shared with friends, neighbors, colleagues and other researchers, far and wide.
